PT-141 (Bremelanotide) vs Palmitoyl Dipeptide-6
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & Libido
PT-141 (Bremelanotide)Skin & CosmeticAnti-Aging & Longevity
Palmitoyl Dipeptide-6- Summary
- PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
- Palmitoyl Dipeptide-6 is a synthetic dipeptide (lysine-threonine) with a palmitoyl fatty acid tail, designed to penetrate the skin barrier and stimulate the extracellular matrix components essential for skin firmness. It activates fibronectin and type IV collagen synthesis, improving skin density and firmness particularly in mature or sagging skin.
- Half-Life
- 2–3 hours
- Not applicable (topical)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 0.5–1.75 mg
- 0.005–0.05% in formulation
- Frequency
- As needed (not daily)
- Once or twice daily
- Key Benefits
- Enhances sexual desire and libido in both men and women
- Improves arousal through central nervous system activation
- Effective for psychological erectile dysfunction
- Works for female sexual arousal disorder
- May improve sexual satisfaction and intensity
- Fast-acting — effects within 45–60 minutes
- FDA-approved for HSDD in premenopausal women
- Increases skin firmness and density
- Stimulates fibronectin and collagen IV production
- Strengthens the dermal-epidermal junction
- Reduces skin sagging in mature skin
- Improves skin texture and smoothness
- Supports extracellular matrix integrity
- Side Effects
- Nausea (most common — 40% of users in clinical trials)
- Facial flushing and warmth
- Transient blood pressure changes (typically increase then normalize)
- Headache
- +2 more
- Generally well-tolerated
- Rare mild skin irritation in sensitive individuals
- No known systemic effects at cosmetic concentrations
- Stacks With
- —
- —